BridgeBio Pharma (BBIO) vs Summit Therapeutics (SMMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BridgeBio Pharma (BBIO) has outperformed Summit Therapeutics (SMMT) over the past year, gaining 22.6% versus a loss of 19.5%. Over five years, SMMT leads with a +248.5% price change compared with +38.6% for BBIO. Summit Therapeutics is the larger company by market cap ($13.47 billion vs $12.71 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBIO | SMMT |
|---|---|---|
| Share price | $65.00 | $16.89 |
| Market cap | $12.71B | $13.47B |
| 1-day change | -2.26% | -5.93% |
| YTD return | -13.06% | +2.63% |
| 1-year return | +22.65% | -19.47% |
| 5-year return | +38.60% | +248.54% |
| EPS (TTM) | $-3.56 | $-1.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $502.08M | — |
| Revenue growth (YoY) | +126.26% | — |
| Net income (latest FY) | $-732.94M | $-1.08B |
| Gross margin | 95.82% | — |
| Operating margin | -104.25% | — |
| Net margin | -145.98% | — |
| 52-week high | $93.42 | $29.23 |
| 52-week low | $52.75 | $12.07 |
| Distance from 52-week high | -30.42% | -42.23% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +67.77% | +76.19% |
| Average volume | 2.75M | 5.76M |
| Shares outstanding | 195.49M | 797.75M |
| Employees | 999 | 265 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BBIO has outperformed SMMT by 42.1 percentage points over the past year.
About BridgeBio Pharma
BBIO stock →BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.
Health Care · Biotechnology: Pharmaceutical Preparations · 999 employees
About Summit Therapeutics
SMMT stock →Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
Health Care · Biotechnology: Pharmaceutical Preparations · 265 employees
BBIO vs SMMT FAQ
Which is bigger, BridgeBio Pharma or Summit Therapeutics?
Summit Therapeutics (SMMT) is larger, with a market capitalization of $13.47B compared with $12.71B for BridgeBio Pharma (BBIO).
Which stock has performed better over the past year, BBIO or SMMT?
BBIO returned +22.65% over the past 12 months, compared with -19.47% for SMMT (price return, excluding dividends). Past performance does not predict future results.
Are BridgeBio Pharma and Summit Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.